Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Completed Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0029527 (Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00397384Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerTreatment